Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
J Mol Microbiol Biotechnol ; 5(2): 97-104, 2003.
Artigo em Inglês | MEDLINE | ID: mdl-12736532

RESUMO

Virus-like particles (VLPs) containing heterologous proteins are often used as vaccines. Two approaches for the construction of bi-functional VLPs using hybrid protein pl-380 of the TY1 transposon of Saccharomyces yeast are described. We have shown that both C- and N-termini of p1-380 can be used for the expression of heterologous peptides. Peptides from A. Fumigatus Asp f 2, expressed at the C- and/or N-termini of p1-380, did not interfere with VLP self-assembling, were accessible for antibodies and hence were exposed at the VLP surface. Another way to obtain bivalent VLPs is the formation of mixed particles, which co-express two hybrid pl proteins with different heterologous protein fragments at the C-terminus. To do it the yeast cells were transfected with a mixture of two recombinant DNA coding Asp f 2 peptide and green fluorescent protein (Gfp). We have shown that both Asp f 2 peptide and Gfp are expressed within the same particle. To evaluate biological activity of bi-functional VLP a construction containing peptides representing dominant T- and B-cell epitopes of Asp f 2 was produced. Bi-functional particles were more potent in stimulating memory immune responses. These results demonstrate new possibilities of pl-380 based expression system to produce multifunctional VLPs.


Assuntos
Proteínas Fúngicas/genética , Retroelementos/genética , Saccharomyces cerevisiae/genética , Vírion/imunologia , Vírion/metabolismo , Sequência de Aminoácidos , Animais , Aspergillus fumigatus , Epitopos de Linfócito B , Epitopos de Linfócito T , Proteínas Fúngicas/química , Proteínas Fúngicas/metabolismo , Proteínas de Fluorescência Verde , Imunização , Epitopos Imunodominantes , Proteínas Luminescentes/genética , Proteínas Luminescentes/metabolismo , Camundongos , Camundongos Endogâmicos BALB C , Dados de Sequência Molecular , Peptídeos/química , Peptídeos/metabolismo , Proteínas Recombinantes de Fusão , Vírion/genética
2.
Immunopharmacol Immunotoxicol ; 20(1): 119-33, 1998 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-9543703

RESUMO

Milife is a novel immunomodulator derived from the fungus Fusarium Sambucium. In this study we examined immunomodulatory properties of Milife in 10 months-old BLRB mice. Milife was given to mice orally in a daily dose of 1 mg per mouse, for 2 to 6 days. Groups of mice were sacrificed on days 2, 4, and 6 of treatment, and 3 weeks after completion of a 6 days treatment with Milife, and lymphoid organs were obtained for analysis. Milife administration led to rapid and significant increase in total leukocyte and lymphocyte numbers in peripheral blood that persisted for at least 3 weeks after a 6 days treatment. Cellularity of lymph nodes, bone marrow and thymus increased significantly at days 4 and 6 of treatment, but returned to pretreatment levels after Milife discontinuation. Though total splenocyte numbers did not change dramatically, there occurred delayed increase in CD4+ cells in the spleen 3 weeks following treatment. Preferential accumulation of CD4+ cells was also consistently found in peripheral blood, with the peak being observed at day 6 of treatment. As a result, CD4/CD8 ratio in blood and spleen was significantly higher in treated than in untreated mice. Splenocytes from treated mice proliferated more vigorously in response to Con A. When added in vitro, Milife also mildly costimulated Con A-induced proliferation of splenocytes from intact animals. In conclusion, we have found that Milife can stimulate leuko- and lymphopoesis in BLRB mice, in particular, accumulation of CD4+ T cells in peripheral lymphoid organs. We conclude that Milife may represent an immunomodulator with the potential to correct T cell dysfunction in patients with immunodeficiency.


Assuntos
Adjuvantes Imunológicos/farmacologia , Fusarium/química , Animais , Misturas Complexas/isolamento & purificação , Misturas Complexas/farmacologia , Leucócitos/efeitos dos fármacos , Ativação Linfocitária/efeitos dos fármacos , Linfócitos/efeitos dos fármacos , Camundongos
3.
J Immunol Methods ; 159(1-2): 17-27, 1993 Feb 26.
Artigo em Inglês | MEDLINE | ID: mdl-8445249

RESUMO

The proliferative response of CTLL-2 cells to human recombinant interleukin-2 (IL-2) can be modeled mathematically using enzyme kinetic equations. This approach has been used to analyze dose-response curves (IL-2 concentration vs. level of proliferation) measured by MTT and [3H]TdR assays. The values of functional dissociation constants, equivalent to IL-2 concentrations giving 50% of the maximal response, depended on the cell concentration and increased from 4 to 60 pM for the [3H]TdR assay and from 40 to 140 pM for the MTT assay when the cell concentration was increased from 2 x 10(3) to 4 x 10(4) cells/well. The types of inhibition and dissociation constants for various inhibitors of IL-2-dependent proliferation such as mAbs against IL-2 receptor (7D4 and AMT13) and normal mouse serum (NMS) were also analyzed. Both mAbs exhibited competitive mechanisms of inhibition whereas NMS inhibited IL-2-driven proliferation in a mixed manner. Two gel-filtration fractions of NMS with inhibitory activity manifested different types of inhibition: purely competitive type of inhibition in the case of a 10-15 kDa fraction and a mixed type of inhibition for a 100-150 kDa fraction. The proposed model can also be used for quantitative analysis of the influence of various factors (pH, temperature, cultivation condition) on the level of proliferation.


Assuntos
Interleucina-2/farmacologia , Ativação Linfocitária/efeitos dos fármacos , Linfócitos T Citotóxicos/imunologia , Animais , Anticorpos Monoclonais/imunologia , Linhagem Celular , Relação Dose-Resposta a Droga , Interleucina-2/antagonistas & inibidores , Masculino , Matemática , Camundongos , Camundongos Endogâmicos C57BL , Modelos Biológicos , Ratos , Ratos Wistar , Receptores de Interleucina-2/fisiologia , Proteínas Recombinantes/farmacologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...